Matches in Wikidata for { <http://www.wikidata.org/entity/Q80315937> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q80315937 description "article scientifique (publié 2007)" @default.
- Q80315937 description "artikull shkencor i botuar më 01 janar 2007" @default.
- Q80315937 description "artículu científicu espublizáu en xineru de 2007" @default.
- Q80315937 description "im Jahr 2007 veröffentlichter wissenschaftlicher Artikel" @default.
- Q80315937 description "scientific article published on 01 January 2007" @default.
- Q80315937 description "wetenschappelijk artikel" @default.
- Q80315937 description "наукова стаття, опублікована в січні 2007" @default.
- Q80315937 name "[The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration]" @default.
- Q80315937 name "[The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration]" @default.
- Q80315937 name "[The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration]" @default.
- Q80315937 type Item @default.
- Q80315937 label "[The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration]" @default.
- Q80315937 label "[The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration]" @default.
- Q80315937 label "[The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration]" @default.
- Q80315937 prefLabel "[The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration]" @default.
- Q80315937 prefLabel "[The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration]" @default.
- Q80315937 prefLabel "[The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration]" @default.
- Q80315937 P1433 Q80315937-3056476D-3C6D-4D3E-8F19-03454FE245FE @default.
- Q80315937 P1476 Q80315937-0BB7D78C-DCD4-4203-A9BB-5090EC56BFDA @default.
- Q80315937 P2093 Q80315937-1101C5B3-9656-42D4-AFE6-1EE25DADBC1E @default.
- Q80315937 P2093 Q80315937-1B39504A-8C4A-4522-8FAD-28215CF80B2E @default.
- Q80315937 P2093 Q80315937-3BD1B247-5137-4FC4-8E11-4489A2D696B3 @default.
- Q80315937 P2093 Q80315937-456000BA-36FA-423F-A19D-27A976C69E1E @default.
- Q80315937 P2093 Q80315937-4C3F22C1-EC3C-442D-BCBB-04D551A26FC0 @default.
- Q80315937 P2093 Q80315937-6C337F4F-FB92-4962-8B7D-974CA2F2708C @default.
- Q80315937 P2093 Q80315937-723BC1E8-EA9F-4CB1-AD8F-E952A19ECE16 @default.
- Q80315937 P2093 Q80315937-AEB40822-0716-4F00-9CDE-ABC1F0A57A54 @default.
- Q80315937 P2093 Q80315937-D6BDC84C-2489-4A3D-963A-8259FD5712B9 @default.
- Q80315937 P2093 Q80315937-F3BB6C55-1A3F-4A54-BE07-154BB9D67F89 @default.
- Q80315937 P304 Q80315937-71C2DB29-C5EF-44FA-8CEB-27B84CC2A1EE @default.
- Q80315937 P31 Q80315937-F60F3D74-A33B-4EC0-B28A-6AB505C3BFB9 @default.
- Q80315937 P433 Q80315937-B2B09E5D-74D1-4486-89AD-5BE18B1B0487 @default.
- Q80315937 P478 Q80315937-2860524E-A2CD-4409-9F5D-68D86A724AE5 @default.
- Q80315937 P577 Q80315937-E68121E4-FBAE-46D2-807B-0E300971CA73 @default.
- Q80315937 P698 Q80315937-B0E3BE81-B3EE-43BF-A943-C8B6627434FE @default.
- Q80315937 P921 Q80315937-75BAE268-78D8-480D-AD57-7676774B5C67 @default.
- Q80315937 P921 Q80315937-8E680A58-BBDC-4E8D-AA8A-287C235233CD @default.
- Q80315937 P921 Q80315937-E01CCD74-6F0F-466C-99D1-ADACB22A3B81 @default.
- Q80315937 P698 17495849 @default.
- Q80315937 P1433 Q15751978 @default.
- Q80315937 P1476 "[The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration]" @default.
- Q80315937 P2093 "E B Maĭkov" @default.
- Q80315937 P2093 "E I Chazov" @default.
- Q80315937 P2093 "I N Bregvadze" @default.
- Q80315937 P2093 "Iu L Klimenko" @default.
- Q80315937 P2093 "L V Rozenshtraukh" @default.
- Q80315937 P2093 "M Iu Smirnova" @default.
- Q80315937 P2093 "O A Bil'dinov" @default.
- Q80315937 P2093 "S F Sokolov" @default.
- Q80315937 P2093 "S P Golitsyn" @default.
- Q80315937 P2093 "T L Kratskina" @default.
- Q80315937 P304 "48-55" @default.
- Q80315937 P31 Q13442814 @default.
- Q80315937 P433 "3" @default.
- Q80315937 P478 "47" @default.
- Q80315937 P577 "2007-01-01T00:00:00Z" @default.
- Q80315937 P698 "17495849" @default.
- Q80315937 P921 Q1729126 @default.
- Q80315937 P921 Q18212318 @default.
- Q80315937 P921 Q815819 @default.